Claim Missing Document
Check
Articles

Found 28 Documents
Search

Respons imun seluler terhadap antigen E2, E6, dan E7 HPV16: Pemanfaatannya pencegahan dan terapi kanker serviks Utami, Mardhah Sastri; Bela, Budiman
Indonesian Journal of Health Science Vol 4 No 5 (2024)
Publisher : PT WIM Solusi Prima

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.54957/ijhs.v4i5.1088

Abstract

HPV merupakan kelompok virus penyebab kanker serviks. HPV16 menyebabkan 46-63% karsinoma sel skuamosa serviks. HPV16 terdiri dari 3 region siklus sel, yaitu early region (E), long control region (LCR), dan late region (L). Early region yang berasal dari protein E1, E2, E4, E5, E6, dan E7 berperan dalam ekspresi gen virus, replikasi virus, dan siklus hidup virus. Virus akan mengekspresikan protein E1 dan E2 kemudian terjadi delesi, dan sel yang terinfeksi akan berdiferensiasi dan mengekspresikan E6 dan E7. Ekspresi E6 dan E7 akan menurunkan ekspresi TLR9, IFN-1, dan supresi sitokin proinflamasi. Respons imun yang menurun menyebabkan sel yang terinfeksi berdiferensiasi menjadi sel kanker. Vaksinasi profilaksis digunakan sebagai pencegahan dan pengendalian infeksi virus HPV16, tetapi tidak dapat melindungi individu yang sudah terinfeksi dari perkembangan infeksi virus dan sel abnormal. Oleh karena itu, vaksinasi terapeutik diperlukan untuk imunoterapi kanker. Antigen HPV16 yang terdiri dari E2, E6, dan E7 diharapkan menjadi target yang baik. Antigen E2, E6, dan E7 bertujuan untuk mengaktifkan respons imun spesifik yang diperantarai sel untuk memfagositosis sel yang terinfeksi. Antigen diproses oleh sel dendritik dan kemudian disajikan kepada molekul MHC. MHC II akan merangsang respons sel T CD4+ terhadap protein yang akan membantu sel T CD8+ sitotoksik. Antigen disajikan oleh MHC I untuk dipresentasikan ke sel T CD8+ sitotoksik untuk mengeliminasi sel yang terinfeksi. Antigen E2, E6, dan E7 untuk imunoterapi guna mencegah perkembangan sel abnormal sehingga tidak berkembang menjadi kanker.
Uji In Vitro Beberapa Kombinasi Antibiotik Antipseudomonas terhadap Pseudomonas aeruginosa yang Resisten terhadap Karbapenem Prasetyo, Dimas Seto; Herna, Herna; Mursinah, Mursinah; Ibrahim, Fera; Bela, Budiman
Jurnal Kefarmasian Indonesia VOLUME 12, NOMOR 1, FEBRUARI 2022
Publisher : Pusat Penelitian dan Pengembangan Biomedis dan Teknologi Dasar Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22435/jki.v0i0.5008

Abstract

Lower respiratory tract, sepsis, or urinary tract infection caused by the multidrug resistance Pseudomonas aeruginosa is common in the hospital, especially in the ICU wards. The treatment against this bacteria requires combination of antibiotics with different mechanism of actions. In this study, several combinations of antibiotics were evaluated in vitro against carbapenem-resistant P. aeruginosa isolated from the ICU of Cipto Mangunkusumo Hospital. The combination of antibiotics tested were ceftazidime-amikacin, ceftazidime-ciprofloxacin, and ciprofloxacin-amikacin. Checkerboard assay to the combination of antibiotics was conducted to assess the in vitro synergistic activity. A total of 22 P. aeruginosa isolates were collected, 16 of them were resistant to ceftazidime, ciprofloxacin, amikacin, as well as carbapenem. The result revealed that the combination of ceftazidime and amikacin showed promising synergistic activity. Conversely, no synergitic activities were shown by the combination of ceftazidime-ciprofloxacin and ciprofloxacin-amikacin. The combination of ceftazidime-amikacin may has potential effect againsts carbapenem-resistant P. aeruginosa in vitro.
THE CURRENT STRATEGIES, RECENT PROGRESS AND REMAINING CHALLENGES FOR DEVELOPING MRNA VIRAL VACCINE Irawan, Priscilla Felicia Apriliani; Bela, Budiman
Jurnal Bioteknologi & Biosains Indonesia (JBBI) Vol. 11 No. 1 (2024)
Publisher : BRIN - Badan Riset dan Inovasi Nasional

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55981/jbbi.2024.6422

Abstract

The mRNA expression system has revolutionised biotechnology, notably in viral mRNA vaccine development, cancer immunotherapy, and gene therapy. However, recent safety concerns regarding the COVID-19 mRNA vaccine have emerged, particularly regarding its rare adverse effects and its possible connection to cancer. This review explains several approaches used in developing viral mRNA vaccines, the past obstacles solved in generating the current COVID-19 mRNA vaccine, and finally the current advancements and ongoing challenges in the viral mRNA vaccine field. We particularly focus on strategies and methods to improve the safety and translation efficiency of the mRNA vaccine, such as enhancing the vaccine’s transfection specificity to targeted dendritic cells (DC) and using viral IRES or self-amplifying mRNA format to improve mRNA translation efficiency.
Pemilihan Peptida Immunogenik E6 Human Papiloma Virus 16 sebagai Kandidat Vaksin kuratif dengan menggunakan Next-Generation IEDB Tools Widyaningtyas, Silvia Tri; Pratiwi, Ekawati Betty; Bela, Budiman
InaBHS (Indonesian Journal of Biomedicine and Health Science) Vol 3 No 2 (2024): Indonesian Journal of Biomedicine and Health Science
Publisher : Fakultas Kedokteran UGJ Cirebon

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33603/inabhs.v3i2.10519

Abstract

ABSTRAK Kanker serviks atau kanker mulut rahim merupakan salah satu penyebab kematian tinggi sampai saat ini. Kanker ini dikaitkan dengan infeksi Human Pappiloma virus (HPV). Vaksinasi merupakan salah satu metode pencegahan yang cukup efektif untuk mencegah kanker serviks. Vaksin yang beredar saat ini efektif untuk mencegah infeksi HPV, namun kurang efektif jika diberikan pada orang yang telah terinfeksi. Hal tersebut dikaitkan dengan jalur kekebalan tubuh yang diinduksi oleh vaksin tersebut. Dalam penelitian ini dirancang antigen HPV 16 yang dapat digunakan dalam pengembangan vaksin terapetik yang ditujukan untuk meningkatkan respon kekebalan seluler yand secara spesifik dapat menghancurkan sel kanker servik. Pemilihan dan karakterisasi antigen dilakukan dengan menerapkan Bioinformatika. Parameter yang dinilai antara lain kemampuan antigen diproses dan dipresentasikan oleh sel tubuh pada sel kekebalan tubuh yang bertanggung jawab pada eliminasi sel kanker, yaitu sel CD8. Hasil studi menunjukkan diperoleh epitop CD8 yang dikenali oleh beberapa jenis HLA. Bioinformatika dapat digunakan untuk mencari epitop.
THE CURRENT STRATEGIES, RECENT PROGRESS AND REMAINING CHALLENGES FOR DEVELOPING MRNA VIRAL VACCINE Irawan, Priscilla Felicia Apriliani; Bela, Budiman
Jurnal Bioteknologi & Biosains Indonesia (JBBI) Vol. 11 No. 1 (2024)
Publisher : BRIN - Badan Riset dan Inovasi Nasional

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55981/jbbi.2024.6422

Abstract

The mRNA expression system has revolutionised biotechnology, notably in viral mRNA vaccine development, cancer immunotherapy, and gene therapy. However, recent safety concerns regarding the COVID-19 mRNA vaccine have emerged, particularly regarding its rare adverse effects and its possible connection to cancer. This review explains several approaches used in developing viral mRNA vaccines, the past obstacles solved in generating the current COVID-19 mRNA vaccine, and finally the current advancements and ongoing challenges in the viral mRNA vaccine field. We particularly focus on strategies and methods to improve the safety and translation efficiency of the mRNA vaccine, such as enhancing the vaccine’s transfection specificity to targeted dendritic cells (DC) and using viral IRES or self-amplifying mRNA format to improve mRNA translation efficiency.
Expression and Purification of Novel Peptide-Based Recombinant Proteins Targeting Breast Cancer Stem Cells Agusta, Istiqomah; Triwidyaningtyas, Silvia; Bela, Budiman; Mardiana, Mardiana; Wanandi, Septelia Inawati
Proceedings Book of International Conference and Exhibition on The Indonesian Medical Education Research Institute Vol. 9 No. - (2025): Proceedings Book of International Conference and Exhibition on The Indonesian M
Publisher : Writing Center IMERI FMUI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69951/proceedingsbookoficeonimeri.v9i-.327

Abstract

Introduction: Peptides with specific affinity toward breast cancer stem cells (BCSCs), including GYSASRSTIPGK and GAIRIRLSEPLS, have gained interest in targeted cancer diagnostics; however, the low abundance of BCSCs often results in limited detection sensitivity. This study addresses this limitation by conjugating BCSC-specific peptides to self-assembling Human Papillomavirus (HPV16) L1 protein, resulting in virus-like particles composed of 72 pentamers that provide substantial signal amplification. In addition, the SpyTag–SpyCatcher system derived from the Streptococcus pyogenes CnaB2 domain provides a robust strategy to enhance peptide–protein stability. Objectives: This study aimed to express and purify three recombinant proteins as key components for assembling a BCSC-specific diagnostic construct: HPV16 L1–SpyTag, SpyCatcher–GYSASRSTIPGK, and SpyCatcher–GAIRIRLSEPLS. Methods: Recombinant genes encoding the target proteins were expressed in Escherichia coli (E. coli) BL21(DE3) following IPTG induction for 1–4 hours. Bacterial cells were harvested and lysed under native or denaturing conditions, and recombinant proteins were purified using Ni-NTA affinity chromatography. Results: SDS–PAGE analysis showed clear bands at the expected molecular weights for HPV16 L1–SpyTag (58.5 kDa), SpyCatcher–GYSASRSTIPGK, and SpyCatcher–GAIRIRLSEPLS (~15 kDa), with induction-dependent increases in band intensity. The SpyCatcher–peptide fusions were predominantly soluble and purified under native conditions, whereas HPV16 L1–SpyTag was largely insoluble and required denaturing purification. Conclusion: HPV16 L1–SpyTag and SpyCatcher–peptide fusions were successfully expressed and purified in E. coli, establishing a versatile platform with potential to enhance BCSC-targeted detection and treatment strategies in breast cancer. 
Mengatasi Tantangan Skrining HPV pada Perempuan: Sebuah Kajian Umum Budiman Bela; Soni Hartono; Ekawati Betty Pratiwi; Hesti Pramesti Cahyani; Silvia Tri Widyaningtyas
Majalah Kedokteran Indonesia Vol 75 No 2 (2025): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.75.2-2025-1898

Abstract

Introduction: A major challenge in the success of HPV screening programs is achieving 70% coverage of women aged 30-69. This study conducted a survey to examine the factors influencing the willingness of woman in that age group to actively engage HPV screening program.Method: Socio-demographic data, knowledge levels, cervical cancer screening uptake, and willingness to participate in the government’s routine screening program were collected digitally using cross-sectional study. Factors associated with knowledge, participation, and willingness to engage program measured using logistic regression analysis.Result: Among the 87 eligible respondents, 96.6% had heard about cervical cancer mostly via internet, and 51% categorized as having low level knowledge. The percentage of participants willingness to participate in program was 67.82% below the percentage government target coverage. Factors correlated with willingness included: age group 36-40 (aOR = 1.865, 95% CI = 0.567-6.129) and 41-45 (aOR = 2.93, 95% CI = 0.762-11.272), monthly household expense (aOR = 1.682, 95% CI = 0.684-4.138), having relatives suffer cervical cancer (aOR = 2.764, 95% CI = 0.790-9.672), history of HPV vaccination (aOR = 1.187, 95% CI = 0.593-7.539).Conclusion: Respondent willingness to participate in HPV screening program remains to be improved. Various ways to increase participation in screening programs need to be developed to reach various populations of women.
Demographic, Clinical, and Antibiotic Exposure Factors Associated with Carbapenem-Resistant Acinetobacter baumannii: An Eight-Year Retrospective Study Angky Budianti; Dzaki Fadlurrahman Ayyasy; Mubarokah Mubarokah; Victor Sitorus; Yulia Rosa Saharman; Budiman Bela; Anis Karuniawati
Jurnal Kesehatan dan Kedokteran Vol. 5 No. 3 (2026): Oktober: Jurnal Kesehatan dan Kedokteran
Publisher : Asosiasi Dosen Muda Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56127/jukeke.v5i3.3072

Abstract

Antimicrobial resistance is a major global health challenge, and carbapenem-resistant Acinetobacter baumannii (CRAB) is of particular concern because of its high level of resistance, limited therapeutic options, and substantial burden in healthcare-associated infections. Identifying patient characteristics and antibiotic exposure associated with CRAB is essential to support effective antimicrobial stewardship and infection prevention strategies. Objective: This study aimed to analyze the association of demographic factors, including age and comorbidities, clinical diagnosis or manifestations, and a history of carbapenem use within the previous month with CRAB among clinical isolates examined at the Clinical Microbiology Laboratory, Faculty of Medicine, Universitas Indonesia, during 2017–2024. Methodology: This quantitative study employed a retrospective cross-sectional design using secondary laboratory and clinical data. Samples were selected through total sampling from patients with clinical specimens yielding A. baumannii. Descriptive analysis was used to characterize the study population, while Chi-square tests were applied to assess associations between the investigated factors and carbapenem resistance. Findings: A total of 172 A. baumannii clinical cultures were identified, of which 118 (68.6%) were CRAB. Age was significantly associated with CRAB (p=0.004), with patients aged >59 years representing the largest CRAB group. Clinical diagnosis or manifestation was also significantly associated with CRAB (p=0.005), with respiratory tract infection being the most frequent manifestation. Previous carbapenem use within one month was significantly associated with CRAB (p=0.009), with an odds ratio of 8.33 (95% CI: 1.48–46.94). In contrast, comorbidity was not significantly associated with CRAB (p=0.665). Implications: These findings support strengthening antimicrobial stewardship, particularly the appropriate use and continuous evaluation of carbapenem therapy, alongside enhanced surveillance and infection prevention measures among high-risk patients. Originality: This study provides local epidemiological evidence from an eight-year clinical dataset and integrates demographic, clinical, and previous carbapenem-exposure factors to characterize CRAB at a clinical microbiology laboratory in Jakarta, thereby contributing institution-specific evidence for CRAB surveillance and prevention strategies.
Co-Authors Ade Pryta Romanauli Simaremare Agusta, Istiqomah Andi Yasmon Andrijono Andrijono Anggraini Alam Angky Budianti Anis Anis Anis Karuniawati Ardiana Kusumaningrum Armi Susandi Aroem Naroeni Aroem Naroeni Ascobat, Purwantyastuti ASRI SULFIANTI Beti Ernawati Dewi Christina, Diana Cintera Rahmagiarti Diah Iskandriati Dian Amirulloh Dimas Seto Prasetyo Dondin Sajuthi Dzaki Fadlurrahman Ayyasy Ekawati Betty Pratiwi Elisna Syahruddin Evy Yunihastuti FERA IBIRAHIM Fera Ibrahim Firdaus Sirait Ganjar Noviar Gede Eko Darmono Geraldine, Vanessa Hanifi, Muhammad Hartiyowidi Yuliawuri Herna Herna Herna, Herna Hertanto, Robby Hesti Pramesti Cahyani Ibnu Agus Ariyanto Iin Maemunah Ingrid S. Surono Irawan, Priscilla Felicia Apriliani Jeanne Adiwinata Pawitan Jeanne Elvia Christian Kamila, Etri Dian Ketut Tuti Parwati Lili Indrawati Mardiana Mardiana Maria Lina R. Maria Lina Rosilawati Melinda Remelia Mubarokah Mubarokah Muhayya, Syarifah Raisha Munasir, Zakiudin Murdani Abdullah Mursinah Mursinah Mursinah Mursinah Ni Ken Ritchie Ni Nengah Dwi Fatmawati Nia Kurniati Nuzli Fahdia Mazfufah Pamungkas, Joko Pauline Phoebe Halim Pramita Gayatri, Pramita Pratiwi, Ekawati Betty Radiana Dhewayani Antarianto SAHLAN, MUHAMAD Sari, Siska Yuliana Satyapertiwi, Dwiantari Septelia I. Wanandi Silvia Tri Widyaningtyas Silvia Triwidyaningtyas Sofy Meilany Soni Hartono Subangkit Subangkit Subiantistha, Tanaya Sugiarta, Gede Yuda SUWIJIYO PRAMONO Triwidyaningtyas, Silvia Utami, Mardhah Sastri Victor Sitorus VIVI SETIAWATY Widianingtyas, Silvia Wiseso, Anggoro Yohda, Masafumi Yulia Rosa Saharman YULIANTY MUHAYAR Yuliar Budi Hartanto Yusmaniar Yusmaniar Yuyun SM Soedarmono Yuyun Soedarmono